Mirna Therapeutics

General Information

We are a clinical-stage biopharmaceutical company developing a broad pipeline of microRNA-based oncology therapeutics. microRNAs are naturally occurring, short ribonucleic acid, or RNA, molecules, or oligonucleotides, that play a critical role in regulating key biological pathways. Misexpression of even a single microRNA can contribute to disease development and tumor suppressor microRNAs are commonly reduced in cancer. Our scientists and others at leading academic institutions have identified numerous tumor suppressor microRNAs that play key roles in preventing normal cells from becoming cancerous and facilitating proper cancer immunosurveillance. We are developing mimics of naturally occurring microRNAs that are designed to restore this tumor suppressor activity and aid appropriate tumor immune response. This approach is known as microRNA replacement therapy. Our lead product candidate, MRX34, a mimic of naturally occurring microRNA-34 (miR-34) encapsulated in a liposomal nanoparticle formulation, is the first microRNA mimic to enter clinical development and has shown preliminary clinical evidence of anti-tumor activity as a single agent in our ongoing Phase 1 clinical trial. We believe that microRNA mimics represent a new paradigm in cancer therapy and have the potential to create a new, important class of effective cancer drugs that can potentially be used alone or in combination with other cancer therapeutics. We plan to develop MRX34 as a monotherapy and in combination with other therapeutic modalities, such as targeted therapies and immuno-oncology agents.

Employees: 24
Founded: 2007
Contact Information
Address 2150 Woodward Street, Suite 100, Austin, TX 78744, US
Phone Number (512) 901-0900
Web Address http://www.mirnarx.com
View Prospectus: Mirna Therapeutics
Financial Information
Market Cap $140.4mil
Revenues $0.0 mil (last 12 months)
Net Income $-23.9 mil (last 12 months)
IPO Profile
Symbol MIRN
Exchange NASDAQ
Shares (millions): 6.3
Price range $7.00 - $7.00
Est. $ Volume $43.8 mil
Manager / Joint Managers Citigroup/ Leerink Partners
CO-Managers Oppenheimer/ Cantor Fitzgerald
Expected To Trade: 10/1/2015
Status: Priced
Quiet Period Expiration Date:
Lock-Up Period Expiration Date:
SCOOP Rating
Rating Change